Literature DB >> 10754451

Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes.

L D DeLeve1, X Wang.   

Abstract

UNLABELLED: This study examines busulfan metabolism. Busulfan given in vivo or in vitro decreased hepatocyte glutathione (GSH) by 60 and 50%, respectively. In vitro, busulfan toxicity was prevented by glutathione S-transferase inhibitors or by antioxidants and led to increased production of oxidized GSH and thiobarbituric acid reactive substances. 'Rescue' from toxicity by GSH precursors was prevented by N,N-bis(2-chloroethyl)-N-nitrosourea (BCNU). Depletion of GSH exacerbated toxicity. In GSH-depleted hepatocytes, busulfan decreased GSH by 95% and BCNU did not prevent rescue by GSH precursors.
CONCLUSIONS: (1) In hepatocytes with normal GSH: busulfan toxicity requires GSH conjugation, does not cause profound GSH depletion and is mediated by oxidative stress. We postulate that a GSH conjugate promotes oxidative stress. (2) In GSH-depleted hepatocytes: busulfan profoundly depletes GSH; toxicity is mediated by oxidative stress and is prevented by restoring GSH levels; cell death may be due to unopposed endogenous oxidative stress. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754451     DOI: 10.1159/000028359

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  30 in total

Review 1.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

3.  MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome.

Authors:  E Efrati; T Zuckerman; E Ben-Ami; N Krivoy
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

4.  Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.

Authors:  Francesca Bonifazi; Gianluca Storci; Giuseppe Bandini; Elena Marasco; Elisa Dan; Elena Zani; Fiorenzo Albani; Sara Bertoni; Andrea Bontadini; Sabrina De Carolis; Maria Rosaria Sapienza; Simonetta Rizzi; Maria Rosa Motta; Martina Ferioli; Paolo Garagnani; Michele Cavo; Vilma Mantovani; Massimiliano Bonafè
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

Review 5.  Reversible and irreversible protein glutathionylation: biological and clinical aspects.

Authors:  Arthur Jl Cooper; John T Pinto; Patrick S Callery
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-05-11       Impact factor: 4.481

Review 6.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

7.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

8.  A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

Authors:  Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

9.  Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Authors:  Paul G Richardson; Vincent T Ho; Sergio Giralt; Sally Arai; Shin Mineishi; Corey Cutler; Joseph H Antin; Nicole Stavitzski; Dietger Niederwieser; Ernst Holler; Enric Carreras; Robert Soiffer
Journal:  Ther Adv Hematol       Date:  2012-08

10.  Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.

Authors:  Islam R Younis; Meenal Elliott; Cody J Peer; Arthur J L Cooper; John T Pinto; Gregory W Konat; Michal Kraszpulski; William P Petros; Patrick S Callery
Journal:  J Pharmacol Exp Ther       Date:  2008-09-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.